	US 12,385,099 B2
	Circulating microrna signatures for ovarian cancer
Dipanjan Chowdhury, Brookline, MA (US); Kevin M. Elias, Brookline, MA (US); Wojciech Fendler, Lodz (PL); and Konrad Stawiski, Lodz (PL)
Assigned to DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US); THE BRIGHAM AND WOMEN'S HOSPITAL, INC., Boston, MA (US); and MEDICAL UNIVERSITY OF LODZ, Lods (PL)
Filed by Dana-Farber Cancer Institute, Inc., Boston, MA (US); The Brigham and Women's Hospital, Inc., Boston, MA (US); and Medical University of Lodz, Lodz (PL)
Filed on Jul. 1, 2022, as Appl. No. 17/810,495.
Application 17/456,478 is a division of application No. 16/476,799, granted, now 11,214,839, issued on Jan. 4, 2022, previously published as PCT/US2018/012982, filed on Jan. 9, 2018.
Application 17/810,495 is a continuation of application No. 17/456,478, filed on Nov. 24, 2021, abandoned.
Claims priority of provisional application 62/444,085, filed on Jan. 9, 2017.
Prior Publication US 2023/0193396 A1, Jun. 22, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6886 (2018.01); C12Q 1/686 (2018.01); G16B 30/00 (2019.01); G16B 40/00 (2019.01)

CPC C12Q 1/6886 (2013.01) [C12Q 1/686 (2013.01); G16B 30/00 (2019.02); G16B 40/00 (2019.02); C12Q 2600/158 (2013.01); C12Q 2600/178 (2013.01)]

8 Claims

1. A method of treating ovarian cancer in a selected subject, the method comprising administering to the selected subject one or more treatments for ovarian cancer, wherein the subject is selected by

(a) detecting in a biological sample obtained from the subject one or more microRNA (miRNA) biomarkers selected from the group consisting of hsa-miR-23b-3p (SEQ ID NO: 29), hsa-miR-29a-3p (SEQ ID NO: 39), hsa-miR-32a-5p (SEQ ID NO: 46), hsa-miR-92a-3p (SEQ ID NO: 47), hsa-miR-150-5p (SEQ ID NO: 83), hsa-miR-200a-3p (SEQ ID NO: 104), hsa-miR-200c-3p (SEQ ID NO: 105), hsa-miR-203a-5p (SEQ ID NO: 106), hsa-miR-320c (SEQ ID NO: 115), hsa-miR-320d (SEQ ID NO: 116), hsa-miR-335-5p (SEQ ID NO: 122), hsa-miR-450b-5p (SEQ ID NO: 149), hsa-miR-1246 (SEQ ID NO: 178), hsa-miR-1307-5p (SEQ ID NO: 182);

(b) determining that the one or more miRNA biomarkers in the sample exhibits fold-change expression relative to a control; and